Chronic idiopathic urticaria (CIU) affects approximately 1.5 million people in the United States. 14,18

  • About 50% of CIU patients continue to experience itch and hives despite H1 antihistamine treatment at FDA-approved doses. 18,19
  • For patients experiencing symptoms of CIU, H1 antihistamines may not be enough to relieve their symptoms.


XOLAIR is a biologic used to treat CIU in patients aged 12 and older who remain symptomatic despite H1 antihistamine treatment.

Additional Information

  • In 2014, XOLAIR became the only FDA-approved CIU treatment other than H1 antihistamines
  • More than 30,000 patients with CIU have been prescribed XOLAIR since 2014 (in the US) 10

Find out more about dosing with XOLAIR for your patients.

XOLAIR for CIU, Patient

Identifying Appropriate Patients

CIU can be an ongoing cycle for patients. CIU is defined as daily or almost daily hives with itch that persist for ≥6 weeks with no known cause. 18,21 Many patients experience symptoms for far longer than 6 weeks, even after a diagnosis is made. 21 One study found that patients searched for an average of 4.4 years before diagnosis. 21

Find out when XOLAIR may be an appropriate treatment option.

Typical CIU Flare Before XOLAIR Treatment

Could Relief From Itch and Hives Be Possible for Your CIU Patients?

XOLAIR for chronic idiopathic urticaria was studied for reduction in weekly itch severity score and weekly hive count score in patients with CIU.
Learn more about the clinical results of XOLAIR in these patients.